secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2022-01-14T23:59:59+00:00
Accession:  0001367644-22-000006
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Founder and Executive Chairman Fuad El-Hibri to retire from Emergent BioSolutions effective April 1, 2022
--------------------------------------------------------------------------------

- Fuad El-Hibri, founder and executive chairman, will retire effective April 1, 2022, after 23 years.
- Retirement not due to any dispute with company, management, or board.
- He will remain available on advisory/consulting basis on terms to be agreed.
- Board expects to name new chair ahead of retirement date.
- Under his leadership, Emergent generated ~$1.6B revenue in 2020 and delivered over 120M dose-equivalents of COVID-19 vaccine.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764422000006/0001367644-22-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764422000006/ebs-20220113.htm
  HTML page:      https://secwatch.observer/filing/0001367644-22-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer